Literature DB >> 26338696

Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules.

Shusuke Tomoshige1, Mikihiko Naito, Yuichi Hashimoto, Minoru Ishikawa.   

Abstract

We have developed a protein knockdown technology using hybrid small molecules designed as conjugates of a ligand for the target protein and a ligand for ubiquitin ligase cellular inhibitor of apoptosis protein 1 (cIAP1). However, this technology has several limitations. Here, we report the development of a novel protein knockdown system to address these limitations. In this system, target proteins are fused with HaloTag to provide a common binding site for a degradation inducer. We designed and synthesized small molecules consisting of alkyl chloride as the HaloTag-binding degradation inducer, which binds to HaloTag, linked to BE04 (2), which binds to cIAP1. Using this system, we successfully knocked down HaloTag-fused cAMP responsive element binding protein 1 (HaloTag-CREB1) and HaloTag-fused c-jun (HaloTag-c-jun), which are ligand-unknown nuclear proteins, in living cells. HaloTag-binding degradation inducers can be synthesized easily, and are expected to be useful as biological tools for pan-degradation of HaloTag-fused proteins.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26338696     DOI: 10.1039/c5ob01395j

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  14 in total

Review 1.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

Review 2.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

3.  REX technologies for profiling and decoding the electrophile signaling axes mediated by Rosetta Stone proteins.

Authors:  Marcus J C Long; Daniel A Urul; Yimon Aye
Journal:  Methods Enzymol       Date:  2019-03-14       Impact factor: 1.600

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

Review 5.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

Review 6.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

7.  Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.

Authors:  Norihito Shibata; Naoki Miyamoto; Katsunori Nagai; Kenichiro Shimokawa; Tomoya Sameshima; Nobumichi Ohoka; Takayuki Hattori; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Cancer Sci       Date:  2017-06-19       Impact factor: 6.716

Review 8.  Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.

Authors:  Minoru Ishikawa; Shusuke Tomoshige; Yosuke Demizu; Mikihiko Naito
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-21

Review 9.  Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.

Authors:  Seonghyeon Moon; Byung-Hoon Lee
Journal:  Mol Cells       Date:  2018-11-07       Impact factor: 5.034

10.  Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.

Authors:  Norihito Shibata; Kenichiro Shimokawa; Katsunori Nagai; Nobumichi Ohoka; Takayuki Hattori; Naoki Miyamoto; Osamu Ujikawa; Tomoya Sameshima; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Sci Rep       Date:  2018-09-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.